Hemogenyx Pharmaceuticals PLC Total Voting Rights
March 28 2024 - 3:00AM
RNS Regulatory News
RNS Number : 5159I
Hemogenyx Pharmaceuticals PLC
28 March 2024
28 March 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx
Pharmaceuticals" or the "Company")
Total Voting Rights
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical group developing new therapies and
treatments for blood diseases, announces that the total issued
share capital of the Company as at 28 March 2024 consists of
1,341,815,988 ordinary shares of 1 pence each, none of which are
held in treasury. Therefore, the total number of voting rights in
the Company is 1,341,815,988.
The figure of 1,341,815,988 ordinary
shares may be used by shareholders of the Company as the
denominator for the calculations by which they will determine if
they are required to notify their investment in, or a change in
their interest in, the share capital of the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVREANDXADALEEA
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2023 to Apr 2024
